Physician profile
Eva E Tomeu
NPI 1972541035
$16,355.54
in general payments reported to CMS, 2019-2025
39 companies · $2,873 in 2025
The $2,873 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,406 · 2022: $2,934 · 2023: $3,931 · 2024: $3,211 · 2025: $2,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $9.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,005.56 |
| Education | $9.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,341.69 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,916.18 | 2021-2025 | Briviact, Nayzilam |
| Abbvie INC. | $1,704.73 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $907.85 | 2021-2025 | Ingrezza |
| Sk Life Science, INC. | $867.95 | 2021-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $572.34 | 2021-2025 | Rytary, Crexont, Ongentys |
| Emd Serono, INC. | $565.91 | 2023-2025 | Mavenclad, Mavenclad |
| Argenx US, INC. | $502.25 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $443.90 | 2022-2025 | Valtoco |
| Lundbeck LLC | $429.32 | 2021-2025 | Rexulti, Vyepti |
| Avanir Pharmaceuticals, INC. | $407.16 | 2021-2022 | |
| Eisai INC. | $392.95 | 2022-2025 | |
| Pfizer INC. | $350.97 | 2023-2025 | |
| Adamas Pharmaceuticals, INC. | $320.21 | 2021 | |
| Genentech USA, INC. | $300.08 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $289.07 | 2021-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $277.72 | 2021-2023 | |
| Tg Therapeutics, INC. | $276.90 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $266.00 | 2023-2025 | Nuedexta, Rexulti |
| Amgen INC. | $263.29 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $221.81 | 2021-2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $218.12 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sumitomo Pharma America, INC. | $213.26 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $194.12 | 2021-2024 | Ultomiris, Soliris |
| Biohaven Pharmaceutical Holding Company LTD. | $163.01 | 2022 | |
| Sunovion Pharmaceuticals INC. | $142.40 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $137.27 | 2022-2023 | Spritam |
| Merz Pharmaceuticals, LLC | $99.44 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Banner Life Sciences, LLC | $77.43 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $73.17 | 2022-2025 | Acthar |
| Avion Pharmaceuticals | $71.18 | 2022-2023 | Dhivy |
| Lilly USA, LLC | $69.99 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.88 | 2021 | |
| Celgene Corporation | $60.69 | 2023-2025 | Zeposia |
| Axsome Therapeutics, INC. | $55.47 | 2025 | Symbravo |
| Averitas Pharma INC. | $29.57 | 2025 | Qutenza |
| Cycle Pharmaceuticals INC | $23.77 | 2025 | Bafiertam |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2021 | |
| Impel Pharmaceuticals INC. | $18.18 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Tomeu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.